| Atara Biotherapeutics, Inc. |
Director |
Common Stock |
31,500 |
$12,254 |
$0.3890 |
23 Jun 2022 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Common Stock |
0 |
$0 |
$41.18 |
01 Aug 2024 |
By Trust |
| Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Common Stock |
0 |
$0 |
$41.18 |
01 Aug 2024 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Performance-based Restricted Stock Units |
0 |
$0 |
$41.18 |
01 Aug 2024 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Restricted Stock Units |
0 |
$0 |
$41.18 |
01 Aug 2024 |
Direct |
| Atara Biotherapeutics, Inc. |
Director |
Non-Qualified Stock Option (Right to Buy) |
31,500 |
|
|
23 Jun 2022 |
Direct |
| Upstream Bio, Inc. |
Director |
Stock Option (Right to Buy) |
17,096 |
|
|
10 Jun 2025 |
Direct |
| Ikena Oncology, Inc. |
Director |
Stock Option (Right to Buy) |
13,419 |
|
|
09 Jun 2022 |
Direct |
| Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Stock Option (Right to Buy) |
0 |
|
|
01 Aug 2024 |
Direct |
| Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
14 Sep 2021 |
By Ronald C. Renaud, Jr. Trust - 2007 |
| Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
14 Sep 2021 |
By Ronald Renaud 2014 Irrevocable Family Trust |
| Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
14 Sep 2021 |
Direct |
| Translate Bio, Inc. |
Chief Executive Officer, Director |
Stcok Option (right to buy) |
0 |
|
|
14 Sep 2021 |
Direct |
| Translate Bio, Inc. |
Chief Executive Officer, Director |
Stock Option (right to buy) |
0 |
|
|
14 Sep 2021 |
Direct |